Outlook therapeutics stock

Outlook Therapeutics, Inc. (OTLK) Stock Price, News, Quote …

Performance Outlook ; Market Cap, 297.734M ; Beta (5Y Monthly), 0.68 ; PE Ratio (TTM), N/A ; EPS (TTM), -0.3220 ; Earnings Date, Feb 15, 2023 – Feb 17, 2023.

Outlook Therapeutics Inc. Stock Quote (U.S. – OTLK

OTLK Stock Price | Outlook Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch

OTLK | Complete Outlook Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

OTLK – Outlook Therapeutics Inc Forecast – CNNMoney.com

The 5 analysts offering 12-month price forecasts for Outlook Therapeutics Inc have a median target of 5.00, with a high estimate of 10.00 and a low estimate …

OTLK Outlook Therapeutics Inc – StockTwits

Outlook Therapeutics Inc Stock – OTLK Share Price Today, News and Discussion

för 4 timmar sedan — OTLK Stock Price – Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of …

OTLK Stock Price – Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and

OTLK: Outlook Therapeutics Inc – Stock Price, Quote and News

OTLK: Outlook Therapeutics Inc – Stock Price, Quote and News – CNBC

Outlook Therapeutics Inc OTLK:NASDAQ ; Close. 1.11 quote price arrow down -0.01 (-0.89%) ; Volume. 754,207 ; 52 week range. 0.68 – 2.12 …

Get Outlook Therapeutics Inc (OTLK:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Outlook Therapeutics, Inc. Common Stock (OTLK) – Nasdaq

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for …

Outlook Therapeutics – OTLK Stock Forecast, Price & News

OTLK Stock Forecast, Price & News (Outlook Therapeutics)

Their OTLK share price forecasts range from $4.00 to $7.00. On average, they anticipate the company’s share price to reach $5.75 in the next twelve months. This …

Researching Outlook Therapeutics? Get The Latest OTLK Stock Forecast, Price Target, Headlines, Short Interest at MarketBeat.

Outlook Therapeutics, Inc.: Investor Overview

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic …

OTLK | Outlook Therapeutics Inc. Stock Overview (U.S.: Nasdaq)

OTLK | Outlook Therapeutics Inc. Stock Overview (U.S.: Nasdaq) | Barron’s

Outlook Therapeutics Inc. ; Volume, 512.46K ; Market Value, $284.9M ; Shares Outstanding, 256.67M ; EPS (TTM), -$0.3147 ; P/E Ratio (TTM), N/A.

Complete Outlook Therapeutics Inc. stock information by Barron’s. View real-time OTLK stock price and news, along with industry-best analysis.